Anti-fibrotic action of pirfenidone in Dupuytren's disease-derived fibroblasts

BMC Musculoskeletal Disorders

Volumn 17, Issue 1, 2016, Pages 1-12

  Zhou, Chaoming ^a   Liu, Fang ^a   Gallo, Phillip H ^a   Baratz, Mark E ^a   Kathju, Sandeep ^b   Satish, Latha ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Alpha SMA; Carpal tunnel; Cell contraction; Cell migration; Collagen; Dupuytren's contracture; Palmar fascia fibrosis; Smad2 Smad3

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; PIRFENIDONE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; NONSTEROID ANTIINFLAMMATORY AGENT; PYRIDONE DERIVATIVE; SMAD2 PROTEIN, HUMAN; SMAD3 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN;

ANTIFIBROTIC ACTIVITY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DUPUYTREN CONTRACTURE; EXTRACELLULAR MATRIX; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MYOFIBROBLAST; CELL MOTION; DRUG EFFECTS; METABOLISM; PHOSPHORYLATION; PRECLINICAL STUDY; PRIMARY CELL CULTURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN TYPE I; COLLAGEN TYPE III; DRUG EVALUATION, PRECLINICAL; DUPUYTREN CONTRACTURE; FIBROBLASTS; FIBRONECTINS; HUMANS; PHOSPHORYLATION; PRIMARY CELL CULTURE; PYRIDONES; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84994440997     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-016-1326-y     Document Type: Article

References (50)

1. Rayan GM. Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am. 2007;89:189-98.
2. Shih B, Bayat A. Scientific understanding and clinical management of Dupuytren disease. Nat Rev Rheumatol. 2010;6:715-26.
3. Michou L, Lermusiaux JL, Teyssedou JP, Bardin T, Beaudreuil J, et al. Genetics of Dupuytren's disease. Joint Bone Spine. 2012;79:7-12.
4. Arkkila PE, Kantola IM, Viikari JS. Dupuytren's disease: association with chronic diabetic complications. J Rheumatol. 1997;24(1):153-9.
5. Mikkelsen OA. Dupuytren's disease-initial symptoms, age of onset and spontaneous course. Hand. 1977;9:11-5.
6. Tomasek JJ, Vaughan MB, Haaksma CJ. Cellular structure and biology of Dupuytren's disease. Hand Clin. 1999;15:21-34.
7. Tomasek JJ, Gabbiani G, Hinz B, et al. Myofibroblasts and mechano-regulation of connective tissue remodeling. Nat Rev Mol Cell Biol. 2002;3:349-63.
8. Shaw RB, Chong AK, Zhang A, et al. Dupuytren's disease: history, diagnosis, and treatment. Plast Reconstr Surg. 2007;120:44e-54.
9. Lanting R, Broekstra DC, Werker PM, van den Heuvel ER. A systematic review and meta-analysis on the prevalence of Dupuytren disease in the general population of Western countries. Plast Reconstr Surg. 2014;133:593-603.
10. Dibenedetti DB, Nguyen D, Zografos L, Ziemiecki R, Zhou X. Prevalence, incidence, and treatments of Dupuytren's disease in the United States: Results from a population-based study. Hand (NY). 2011;6:149-58.
11. Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P. Direct and indirect costs associated with Dupuytren's contracture. J Med Econ. 2012;15:664-71.
12. van Rijssen AL, ter Linden H, Werker PM. Five-year results of a randomized clinical trial on treatment in Dupuytren's disease: percutaneous needle fasciotomy versus limited fasciectomy. Plast Reconstr Surg. 2012;129:469-77.
13. Hurst LC, Badalamente MA, Hentz VR, Hotchkiss RN, Kaplan FT, Meals RA, Smith TM, Rodzvilla J. CORD I Study Group. Injectable collagenase clostridium for Dupuytren's contracture. N Engl J Med. 2009;361:968-79.
14. Rozen WM, Edirisinghe Y, Crock J. Late complications of clinical clostridium histolyticum collagenase use in Dupuytren's disease. PLoS ONE. 2012;7(8):e43406.
15. Povlsen B, Singh S. Acute double flexor tendon ruptures following injection of collagenase clostridium histolyticum (Xiapex) for Dupuytren's contracture. BMJ Case Rep. 2014.
16. Worrell M. Dupuytren's disease. Orthopedics. 2012;35:52-60.
17. Badalamente MA, Sampson SP, Hurst LC, Dowd A, Miyasaka K. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg [Am]. 1996;21(2):210-5.
18. Vaughan MB, Howard EW, Tomasek JJ. Transforming growth factor-β1 promotes the morphological and functional differentiation of the myofibroblast. Exp Cell Res. 2000;257:180-9.
19. Satish L, Gallo PH, Baratz ME, Johnson S, Kathju S. Reversal of TGF-β1 stimulation of α-smooth muscle actin and extracellular matrix components by cyclic AMP in Dupuytren's-derived fibroblasts. BMC Musculoskelet Disord. 2011;12:113.
20. Swaney JS, Roth DM, Olson ER, Naugle JE, Meszaros GJ, Insel PA. Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc Natl Acad Sci. 2005;102:437-42.
21. Liu X, Ostrom RS, Insel PA. cAMP-elevating agents and adenylyl cyclase overexpression promote an antifibrotic phenotype in pulmonary fibroblasts. Am J Physiol. 2004;286:C1089-99.
22. Kavitha C, Rajamani K, Vadivel E. Coleus forskohlii- A comprehensive review on morphology, phytochemistry and pharmacological aspects. J Med Plants Res. 2010;4:278-85.
23. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377:1760-9.
24. Al-Bayati MA, Xie Y, Mohr FC, et al. Effect of pirfenidone against vanadate-induced kidney fibrosis in rats. Biochem Pharmacol. 2002;64:517-25.
25. Lee KW, Everett TH, Rahmutula D, et al. Pirfenidone prevents the development of a vulnerable substrate for atrial fibrillation in a canine model of heart failure. Circulation. 2006;114:1703-12.
26. Di Sario A, Bendia E, Macarri G, et al. The anti-fibrotic effect of pirfenidone in rat liver fibrosis is mediated by downregulation of procollagen alpha1 (I), TIMP-1 and MMP-2. Dig Liver Dis. 2004;36:744-51.
27. Armendariz-Borunda J, Lyra-Gonzalez I, Medina-Preciado D, et al. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann Plast Surg. 2012;68:22-8.
28. Lasky J. Pirfenidone. IDrugs. 2004;7(2):166-72.
29. Hewitson TD, Kelynack KJ, Tait MG, et al. Pirfenidone reduces in vitro rat renal fibroblast activation and mitogenesis. J Nephrol. 2001;14(6):453-60.
30. Thannickal YJ, Flaherty KR, Martinez FJ, Lynch JP. iii: Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy. Expert Opin Pharmacother. 2004;5(8):1671-86.
31. Satish L, Palmer B, Liu F, Papatheodorou L, Rigatti L, Baratz ME, Kathju S. Developling an animal model of Dupuytren's diseaseby orthotopic transplantation of human fibroblasts into athymic rat. BMC Musculoskelt Disord. 2015;16:138.
32. Satish L, O'Gorman DB, Johnson S, Raykha C, Gan BS, Wang JH, Kathju S. Increased CCT-eta expression is a marker of latent and active disease and a modulator of fibroblast contractility in Dupuytren's contracture. Cell Stress Chaperones. 2013;18:397-404.
33. Brickley-Parsons D, Glimcher MJ, Smith RJ, Albin R, Adams JP. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg Am. 1981;63(5):787-97.
34. Howard JC, Varallo VM, Ross DC, Faber KJ, Roth JH, Seney S, Gan BS. Wound healing-associated proteins Hsp47 and fibronectin are elevated in Dupuytren's contracture. J Surg Res. 2004;117:232-8.
35. Vi L, Feng L, Zhu RD, Wu Y, Satish L, Gan BS, O'Gorman DB. Periostin differentially induces proliferation, contraction and apoptosis of primary Dupuytren's disease and adjacent palmar fascia cells. Exp Cell Res. 2009;315:3574-86.
36. Krause C, Kloen P, Dijke PT. Elevated transforming growth factor β and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis Tissue Repair. 2011;4:14.
37. Satish L, LaFramboise WA, Johnson S, Vi L, Njarlangattil A, Raykha C, Krill-Burger JM, Gallo PH, O'Gorman DB, Gan BS, Baratz ME, Ehrlich GD, Kathju S. Fibroblasts from phenotypically normal palmar fascia exhibit molecular profiles highly similar to fibroblasts from active disease in Dupuytren's Contracture. BMC Med Genomics. 2012;5:15.
38. Meyer A, Wang W, Qu J, Croft L, Degen JL, Coller BS, Ahamed J. Platelet TGF-β1 contributions to plasma TGF-β1, cardiac fibrosis, and systolic dysfunction in a mouse model of pressure overload. Blood. 2012;119:1064-74.
39. Cutolo CA, Lombardo S, Verticchio Vercellin AC, Bertonr C, De Amici M, Antoniazzi E, Milano G. Cataracts and Dupuytren disease: a case report and review of the literature. Eur J Opthalmol. 2013;23(1):135-7.
40. Shi Q, Liu X, Bai Y, Cui C, Li J, Li Y, Hu S, Wei Y. In vitro effects of pirfenidone on cardiac fibroblasts: proliferation, myofibroblast differentiation, migration and cytokine secretion. PLoS ONE. 2011;6:Article e28134.
41. Lin X, Yu M, Wu K, Yuan H, Zhong H. Effects of pirfenidone on proliferation, migration, and collagen contraction of human Tenon's fibroblasts in vitro Invest. Ophthalmol Vis Sci. 2009;50:3763-70.
42. Xiang XH, Jiang TP, Zhang S, Song J, Li X, Yang JY, Zhou S. Pirfenidone inhibits proliferation, arrests the cell cycle, and downregulates heat shock protein-47 and collagen type I in rat hepatic stellate cells in vitro. Mol Med Rep. 2015;12:309-14.
43. Knobloch K, Redeker J, Vogt PM. Antifibrotic medication using a combination of N-acetyl-L-cystein (NAC) and ACE inhibitors can prevent the recurrence of Dupuytren's disease. Med Hypotheses. 2009;73(5):659-61.
44. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425(6958):577-84.
45. Xu J, Lamouille S, Derynck R. TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 2009;19:156-72.
46. Yuan Q, Wang L, Zhang F, Wang R, Fu X, Peng Z, Ning W, Hu G, Wang Z, Tao L. Fluorofenidone suppresses epithelial-mesenchymal transition and the expression of connective tissue growth factor via inhibiting TGF-beta/Smads signaling in human proximal tubular epithelial cells. Pharmazie. 2011;66(12):961-7.
47. Yang Y, Ye Y, Lin X, Wu K, Yu M. Inhibition of pirfenidone on TGF-beta2 induced proliferation, migration and epithelial-mesenchymal transition of human lens epithelial cells line SRA01/04. PLoS ONE. 2013;8(2):e56837.
48. Choi K, Lee K, Ryu SW, Im M, Kook KH, Choi C. Pirfenidone inhibits transforming growth factor-β1-induced fibrogenesis by blocking nuclear translocation of Smads in human retinal pigment epithelial cell line ARPE-19. Mol Vis. 2012;18:1010-20.
49. Wang J, Yang Y, Xu J, Lin X, Wu K, Yu M. Pirfenidone inhibits migration, differentiation, and proliferation of human retinal pigment epithelial cells in vitro. Mol Vis. 2013;19:2626-35.
50. Rodríguez-Castellanos M, Tlacuilo-Parra A, Sánchez-Enríquez S, Vélez-Gómez E, Guevera-Gutiérrez E. Pirfenidone gel in patients with localized scleroderma: a phase II study. Arthritis Res Ther. 2015;16(6):510.